NCT05455658View on ClinicalTrials.gov

STEMVAC in Patients With Early Stage Triple Negative Breast Cancer

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

33

Participants

Timeline

Start Date

November 17, 2022

Primary Completion Date

July 16, 2026

Study Completion Date

July 16, 2028

Conditions
Anatomic Stage IB Breast Cancer AJCC v8Anatomic Stage II Breast Cancer AJCC v8Anatomic Stage IIA Breast Cancer AJCC v8Anatomic Stage IIB Breast Cancer AJCC v8Anatomic Stage III Breast Cancer AJCC v8Anatomic Stage IIIA Breast Cancer AJCC v8Anatomic Stage IIIB Breast Cancer AJCC v8Anatomic Stage IIIC Breast Cancer AJCC v8Prognostic Stage IB Breast Cancer AJCC v8Prognostic Stage II Breast Cancer AJCC v8Prognostic Stage IIA Breast Cancer AJCC v8Prognostic Stage IIB Breast Cancer AJCC v8Prognostic Stage III Breast Cancer AJCC v8Prognostic Stage IIIA Breast Cancer AJCC v8Prognostic Stage IIIB Breast Cancer AJCC v8Prognostic Stage IIIC Breast Cancer AJCC v8Triple-Negative Breast Carcinoma
Interventions
BIOLOGICAL

CD105/Yb-1/SOX2/CDH3/MDM2-polyepitope Plasmid DNA Vaccine

Given IV

BIOLOGICAL

Sargramostim

Given ID

Trial Locations (3)

21287

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore

53792

University of Wisconsin Carbone Cancer Center, Madison

98109

Fred Hutch/University of Washington Cancer Consortium, Seattle

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

collaborator

University of Wisconsin, Madison

OTHER

lead

University of Washington

OTHER